Equities

Aethlon Medical Inc

Aethlon Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.4243
  • Today's Change0.004 / 1.02%
  • Shares traded541.69k
  • 1 Year change-86.33%
  • Beta1.5767
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.

  • Revenue in USD (TTM)574.25k
  • Net income in USD-12.26m
  • Incorporated1991
  • Employees15.00
  • Location
    Aethlon Medical Inc11555 Sorrento Valley Road, Suite 203SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 459-7800
  • Websitehttps://www.aethlonmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SPO Global Inc838.00k-540.00k1.23m2.00------1.46-85.99-85.99131.76-476.561.76-------113.56-305.39----31.1527.31-64.44-384.85---1.45-----17.09-15.1313.03------
Escalon Medical Corp11.65m-296.71k1.30m38.00--1.26--0.1114-0.0401-0.04011.290.22592.403.757.51306,456.30-1.26-1.76-2.84-3.6744.0744.57-0.5265-0.91140.8927-1.620.1584--13.801.33760.89-17.06-19.85--
Acutus Medical Inc9.55m-9.70m1.36m233.00------0.142-0.33010.09560.3261-0.13530.12111.141.4640,974.25-12.30-46.76-14.84-56.88-24.07-89.12-101.56-773.492.89-4.641.13--136.3627.03-141.35---35.99--
Nemaura Medical Inc0.00-10.65m1.44m36.00---------0.3787-0.37870.00-0.61690.000.00--0.00-117.49-58.18---131.96-------7,384.830.0305-1.4710.81---84.71---1.85--64.14--
Grapefruit USA Inc34.85k-4.37m1.55m9.00------44.46-0.008-0.0080.00006-0.01010.01211.310.22593,872.22-151.85-268.93-----1,304.65-10.09-12,531.68-408.870.0388-1.50-----83.9677.87-35.68------
Bone Biologics Corp0.00-6.10m1.65m2.00--0.4149-----23.10-23.100.003.620.00----0.00-114.93-98.31-189.37--------------0.00-------502.76------
Kelyniam Global Inc517.70k-420.28k1.76m0.00--3.28--3.40-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Aethlon Medical, Inc.574.25k-12.26m2.12m15.00--0.1433--3.69-5.03-5.030.23622.930.0369----38,283.33-78.62-75.30-92.02-84.98-----2,133.17-1,783.78----0.00--95.2130.86-15.55--106.99--
NanoVibronix Inc2.85m-3.20m2.16m10.00--0.6166--0.7581-1.72-1.721.451.260.5160.368313.64285,000.00-57.98-116.16-101.17-169.3668.9850.47-112.35-570.471.38-13.470.00--203.5948.3331.88---34.02--
Dynatronics Corp33.60m-5.14m2.18m154.00--0.2916--0.0648-1.19-1.197.583.041.103.338.31218,173.30-14.35-6.02-19.94-8.3021.3727.33-13.07-4.550.6787-12.560.2188---8.41-8.81-19.84---5.11--
VirExit Technologies Inc0.00-1.80m2.28m-----------0.0932-0.1130.00-0.03670.00-------6,103.43-----------------3.66-----100.00--19.08------
Bioelectronics Corp1.61m-289.82k2.47m9.00------1.53-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Tivic Health Systems Inc1.13m-7.61m2.50m9.00--0.2771--2.21-11.17-11.171.021.460.21840.923717.31126,000.00-146.51---194.55--30.07---670.99--2.07--0.00---36.09--18.34------
Tenon Medical Inc3.21m-14.33m2.77m21.00--8.55--0.8624-7.24-7.241.430.97240.41082.787.25153,047.60-183.10---269.43--54.70---445.77--2.35--0.00--323.73--17.63------
Therapeutic Solutions International Inc98.99k-2.17m2.96m3.00--2.37--29.91-0.0007-0.00070.000030.00030.02871.134.4432,996.67-64.51-162.32-169.11--62.8567.79-2,247.41-2,391.850.0333-4.920.373---52.1395.3543.11------
Data as of May 28 2024. Currency figures normalised to Aethlon Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

1.98%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202421.22k0.81%
Geode Capital Management LLCas of 31 Mar 202420.27k0.77%
BlackRock Fund Advisorsas of 31 Mar 20247.34k0.28%
Group One Trading LPas of 31 Mar 20241.22k0.05%
Tower Research Capital LLCas of 31 Mar 20241.14k0.04%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024299.000.01%
Wells Fargo Clearing Services LLCas of 31 Mar 2024211.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202489.000.00%
UBS Securities LLCas of 31 Mar 202473.000.00%
UBS Financial Services, Inc.as of 31 Mar 202461.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.